The PharMed Group, LLC
Please update to Flash Player 8
Gregg Berkowitz – President
Gregg Berkowitz created The PharMed Group, LLC and PharMed Placement, LLC to provide the medical communications industry with an efficient, reliable resource for all their personnel requirements. Since its inception in 2000, Gregg and PharMed have supported the freelance and full-time personnel efforts of more than 75 clients in the pharmaceutical and medical communications industries.
Prior to the formation of The PharMed Group, LLC, Gregg was an Account Executive with a major telecommunication company specializing in the medical communications business. As the number one ranked salesperson for the MCI WorldCom organization (2001), during a two-year period with the company, Gregg was responsible for the generation of new business in excess of more than $20 million dollars. Working closely with medical communications and health care companies, Gregg was made aware of the critical need for highly qualified science writers, regulatory, and other professional personnel to both complement existing resources and to fill new or open positions. So began the launch of the PharMed businesses: The PharMed Group, LLC and PharMed Placement, LLC.
Kenneth P. Berkowitz, Esq. – Senior Consultant
Kenneth P. Berkowitz, Esq. is a health care industry consultant who provides counsel to the industry on a variety of FDA, health care, and public affairs issues. He specializes in FDA regulatory matters, prescription drug policy issues, and other subjects relating to the approval and marketing of prescription drugs.
Mr. Berkowitz was a former Assistant General Counsel at Hoffmann-La Roche Inc. He also served as Vice President, Public Affairs, Drug Safety and Drug Regulatory Affairs and as a member of the Pharmaceuticals Business Leadership Board.
During his professional career, Mr. Berkowitz has been a key player in major domestic and international policy issues affecting the pharmaceutical industry. Among the critical industry issues that he has played a major role in are Hatch-Waxman patent restoration, health care reform, FDA regulatory reform, and product utilization (appropriate use/ government controls) issues.
In 1992, Mr. Berkowitz chaired the joint PhRMA/BIO Staff Task Force on User Fees that worked with FDA to develop the Prescription Drug User Fees Act (PDUFA). In 1993, he was a recipient of the FDA Commissioner’s Special Citation for providing invaluable assistance to the Food and Drug Administration.
Mr. Berkowitz is a recognized expert on the subject of regulation of prescription drug marketing and promotion. He has been a long time advocate of the importance of advertising and other marketing communications and of their protection under the First Amendment of the United States Constitution. He has spoken on the subject of regulation before major trade associations and educational associations and business schools. In addition, Mr. Berkowitz has created various educational and training programs for individual companies as well as the industry generally. He was the Executive Editor of the authoritative three volume pharmaceutical industry resource: Understanding Promotional and Educational Regulations/Guidelines for Prescription Drugs: A Training Program.
Mr. Berkowitz has served as Vice President, Treasurer, Director, Counsel and Special Advisor to the HealthCare Marketing & Communications Council (HMC) and became President in 2005. The HMC Council is a leading not-for-profit membership organization focusing on training and professional development needs for individuals involved in pharmaceutical marketing and communications.
Mr. Berkowitz also served as Adjunct Assistant Professor at Fairleigh Dickinson University and lecturer at the Amos Tuck School of Business, Dartmouth College and Rutgers University Graduate School of Management. He currently holds a position on the editorial Advisory Board of RX Compliance, an industry newsletter for compliance issues and personnel. He is on the Board of Advisors of the Blanche and Irwin Lerner Center for Management Studies at the Rutgers Business School and has served as a board member for and Vice Chair of the Children’s Research Institute of Children’s National Medical Center (CNMC), and Chairman of the Board of Directors of the Pharmaceutical Education and Research Institute (PERI), a not-for-profit education and training organization for pharmaceutical industry personnel.